Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Case 81% Improvement Relative Risk c19hcq.org Bhattacharya et al. HCQ for COVID-19 PrEP Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Retrospective 106 patients in India Fewer cases with HCQ (p=0.001) Bhattacharya et al., medRxix, doi:10.1101/2020.06.09.20116806 Favors HCQ Favors control
Pre exposure Hydroxychloroquine use is associated with reduced COVID19 risk in healthcare workers
Bhattacharya et al., medRxix, doi:10.1101/2020.06.09.20116806 (Preprint)
Bhattacharya et al., Pre exposure Hydroxychloroquine use is associated with reduced COVID19 risk in healthcare workers, medRxix, doi:10.1101/2020.06.09.20116806 (Preprint)
Jun 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
HCQ reduced cases from 38% to 7%. 106 people. No serious adverse effects.
risk of case, 80.7% lower, RR 0.19, p = 0.001, treatment 4 of 54 (7.4%), control 20 of 52 (38.5%), NNT 3.2.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Bhattacharya et al., 9 Jun 2020, retrospective, India, preprint, 7 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: International Journal of Research in Medical Sciences Bhattacharya R et al. Int J Res Med Sci. 2020 Oct;8(10):3518-3522 www.msjonline.org pISSN 2320-6071 | eISSN 2320-6012 DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20204010 Original Research Article The beneficial role of N-acetylcysteine as an adjunctive drug in treatment of COVID-19 patients in a tertiary care hospital in India: an observational study Raja Bhattacharya1, Maitry Mondal1, Subhendu Bikash Naiya1, Lamsaka Lyngdoh1, Rishav Mukherjee1*, Prabhat K. Singh2 1 Department of Medicine, Medical College and Hospital, Kolkata, West Bengal, India Marwari Relief Society, Kolkata, West Bengal, India 2 Received: 25 August 2020 Revised: 09 September 2020 Accepted: 10 September 2020 *Correspondence: Dr. Rishav Mukherjee, E-mail: mukherjeerishav@gmail.com Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. ABSTRACT Background: N-acetyl cysteine, a mucolytic agent, demonstrates free radical scavenging and anti-inflammatory properties, and prevents endothelial dysfunction by inhibition of NF-KB and formation of no adducts. This has a potential role to tackle cytokine storms, endothelial dysfunction and prothrombotic state observed in COVID-19 manifestations like ARDS and Multi organ dysfunction. Methods: Institution based descriptive cross sectional study, 164 patients from laboratory confirmed RT PCR positive COVID-19 patients, in the study period from 27th May 2020 to 10th August 2020, were assessed, in medical college Kolkata, a dedicated COVID-19 care facility. Results: It was observed that moderate-severe patients who received N-acetyl cysteine along with standard therapy had average hospital stay duration of 12 days, higher rate of discharge, average duration of oxygen therapy of 8 days, less number of deaths and reduced transfer to critical care facilities. Conclusions: N-acetyl cysteine can be considered as an adjunctive therapy with standard protocol driven care, due to its beneficial anti-inflammatory and free radical scavenging properties. Keywords: COVID-19, N-acetyl cysteine, Free radical scavenger, Anti-inflammatory
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit